Skip to main content
. 2020 Apr 10;38(16):1774–1784. doi: 10.1200/JCO.19.02474

FIG A1.

FIG A1.

Kaplan-Meier estimates of 5-year disease-free survival (DFS) per-protocol set population (n = 564). HR, hazard ratio; T-FEC, 3 cycles of docetaxel followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide; XT-XEC, 3 cycles of capecitabine plus docetaxel followed by 3 cycles of capecitabine, epirubicin, and cyclophosphamide.